Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SAT1 | P21673 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 5/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25565761 | 0.87 | ALDH1A1 (0.50) | KMT2AALDH1A1SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL4748879 | 0.85 | — | — | |
| SCHEMBL13612884 | 0.84 | ALDH1A1 (0.45) | KMT2AALDH1A1SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL25565755 | 0.83 | ALDH1A1 (0.47) | CYP2C19KMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL25463224 | 0.82 | ALDH1A1 (0.56) | CYP2C19KMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL15510535 | 0.82 | CYP2C19 (0.44) | CYP2C19MEN1GLAKMT2AALDH1A1 | |
| SCHEMBL12245085 | 0.80 | ALDH1A1 (0.54) | KMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL6552923 | 0.80 | ALDH1A1 (0.44) | CYP2C19KMT2AALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL25832206 | 0.80 | EPHX2 (0.35) | CYP2C19MEN1GLAKMT2AALDH1A1 | |
| SCHEMBL25075483 | 0.79 | ALDH1A1 (0.45) | CYP2C19KMT2AALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2708529-B1 | METHOD FOR MANUFACTURING PARTICLES | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9796831-B2 | Process for producing particles | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-24 | — | — | US | disclosed |
| WO-2017181138-A1 | PHOTODYNAMIC INSECTICIDES | LEISHVAC LLC (US) | 2017-10-19 | — | — | WO | disclosed |
| CN-103974929-B | The manufacture method of the halogen acid salt of haloalkylamine | 住友化学株式会社 | 2016-08-24 | — | — | CN | disclosed |
| CN-103534236-B | Method for producing granules | 住友化学株式会社 | 2016-08-17 | — | — | CN | disclosed |
| CN-103974929-A | Method for producing hydrohalic acid salt of halogenated alkyl amine | SUMITOMO CHEMICAL CO | 2014-08-06 | — | — | CN | disclosed |
| EP-2708529-A1 | METHOD FOR MANUFACTURING PARTICLES | Sumitomo Chemical Company Limited (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-20140065337-A1 | PROCESS FOR PRODUCING PARTICLES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| CN-103534236-A | Method for producing granules | SUMITOMO CHEMICAL CO | 2014-01-22 | — | — | CN | disclosed |
| US-7671080-B2 | 1-benzylindole-2-carboxamide derivatives | N.V. ORGANON (NL) | 2010-03-02 | — | — | US | disclosed |
| US-20080280923-A1 | 1-Benzylindole-2-Carboxamide Derivatives | N.V. ORGANON (NL) | 2008-11-13 | — | — | US | disclosed |
| EP-1940788-A1 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | N.V. Organon (NL) | 2008-07-09 | — | — | EP | disclosed |
| WO-2006100208-A9 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | ORGANON NV (NL) | 2007-11-22 | — | — | WO | disclosed |
| WO-2006100208-A1 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280923-A1 | 1-Benzylindole-2-Carboxamide Derivatives | CNR2, CNR1, HTR2C | CYP2C19 332/4885MEN1 2868/4885GLA 2162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.